CN1107501C - Albendazole emulsion - Google Patents
Albendazole emulsion Download PDFInfo
- Publication number
- CN1107501C CN1107501C CN 99113446 CN99113446A CN1107501C CN 1107501 C CN1107501 C CN 1107501C CN 99113446 CN99113446 CN 99113446 CN 99113446 A CN99113446 A CN 99113446A CN 1107501 C CN1107501 C CN 1107501C
- Authority
- CN
- China
- Prior art keywords
- albendazole
- emulsion
- aib
- mice
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Abstract
The present invention provides a novel albendazole emulsion which is an antiparasitic agent. The albendazole emulsion contains 0.125 to 10.0 (proportion by weight)of albendazole, and also contains liquid grease, an emulsifying agent, a preservative agent and a flavouring agent. The present invention is used for treating echinococcosis and other parasitic diseases, and can increase blood drug level and improve curative effect. The present invention has the advantages of low toxicity, simple preparation, high stability and easy popularization.
Description
The present invention relates to a kind of novel form of antiparasitic albendazole---Albendazole emulsion.
Echinococcosis granulosa in the parasitic disease (echinococcosis granulosa) is a kind of serious infecting both domestic animals and human parasitic disease of NORTHWEST CHINA and southwest, has confirmed that the locality has the provinces, municipalities and autonomous regions of cases of infection to reach 23.During the 1951-1990, province and municipalities such as Xinjiang, Gansu, Qinghai, Ningxia, Tibet and the Inner Mongol are 26065 examples through the echinococcosis people of operative treatment, and the prevalence of crowd's echinococcosis is 0.6-4%.Except that echinococcosis granulosa, China still looks into the echinococcosis multilocularis (echinococcosis multilocularis) of seeing the prognosis extreme difference, is distributed in 49 counties and cities of above-mentioned 6 provinces and regions.Before the seventies, the main Therapeutic Method of echinococcosis is a surgical resection, but can not all deal with problems, and the caused Echinococcus hydatid cyst of a large amount of protoscolex spill and leakages is extensively sent out when postoperative recurrence and operation, and some cases is unsuitable for operation etc.As for the treatment of echinococcosis multilocularis, shift widely because of often existing when making a definite diagnosis, or the histoorgan of heavy damage parasitic site, most cases have been unsuitable for excision, need badly and seek new Therapeutic Method.
After middle nineteen seventies discovery mebendazole is effective to echinococcosis, the echinococcosis that heals with medicine begins to come into one's own, after particularly entering the eighties, World Health Organization (WHO) successively organizes international cooperation twice, comparative observation the curative effect of mebendazole and albendazole (AIb) treatment echinococcosis, think that the curative effect of albendazole is better than mebendazole.In recent years, further carry out clinical treatment research both at home and abroad, it is all effective to capsule type and echinococcosis multilocularis further to prove conclusively albendazole, but is 30-40% to the cure rate of echinococcosis granulosa, thus need the bioavailability that improves albendazole badly, in the hope of the raising curative effect.Zoopery and anthroposcopy result show that albendazole is oral relatively poor from the gastrointestinal absorption, and is converted into albendazole-sulfoxide and Albendazole sulfone rapidly after absorbing, and the former is effective metabolite.Further observe and point out that capsule liquid is relevant with its haemoconcentration with the albendazole-sulfoxide content of cyst wall, also influence the extent of damage of cyst wall tissue.Therefore, the laboratory that has in recent years is devoted to prepare the research of albendazole liposomes, in the hope of by improving the blood drug level of albendazole, increases its curative effect to echinococcosis.
In view of the existing not high defective of albendazole curative effect, the object of the invention is to improve the bioavailability of albendazole, to reach the purpose that improves curative effect.
We can improve albendazole blood drug level according to fat meal, and we are in the test that improves the AIb oral absorption, and the Emulsion of observing AIb can obviously improve blood drug level.Become oral absorption good through the repeated multiple times Experiment Preparation, the curative effect height does not increase toxic A Benda azoles Emulsion.Through series of experimental research, selected for use aqueous oils and fats of edible and albendazole to be prepared into Emulsion, estimate with mice, the albendazole blood drug level of an Orally taken emulsion is high approximately 1 times than suspension, the curative effect of its anti-mice echinococcosis also is better than Albendazole suspension, so be worth Albendazole emulsion is developed into a kind of novel form of treatment echinococcosis.
Albendazole emulsion of the present invention is made (consumption all is weight percentage) by following component
Albendazole 0.125-10.0
Aqueous oils and fats 10-57
Emulsifying agent 1-4
Antiseptic 0.1-0.18
Flavoring agent 0.015-0.1
Water adds to 100
Wherein aqueous oils and fats is the aqueous oils and fats of edible, can be edible soybean oil, salad oil and corn wet goods.
Wherein antiseptic is sorbic acid, benzoic acid etc.
Wherein emulsifying agent is a gum arabic powder, xanthan rubber powder, tragakanta etc.
Flavoring agent is vanillin, sweet glucose etc.
The present invention contains the 6.25-25mg albendazole by every gram and makes Orally taken emulsion.
Compound method: by above-mentioned formula proportion, take by weighing albendazole respectively, the amount of aqueous oils and fats and emulsifying agent mix homogeneously in emulsator adds about 60% of total water, start emulsifying to colostrum forms, in addition with the antiseptic after the weighing, flavoring agent is put in the container, adds surplus water (stay a little stand-by) and stirs, merge to Ruzhong just, the low amounts of water eluant container that reuse stayed is incorporated in Ruzhong just, the start stirring.
The present invention can improve blood drug level, gavages the blood drug level of the mice of AIb Emulsion by mensuration, finds that the blood drug level of mouse gavaging AIb Emulsion is than high about 1 times of 1% tragakanta liquid under the identical condition of albendazole content.
Assay method is as follows:
Materials and methods:
Mice: body weight 20-26g is provided by animal housing of Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences.The quality certification is: moving word 02-32-2 number of doctor.
AIb Emulsion is provided by Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences pharmaceutical chemistry study on the synthesis chamber.The concentration of AIb is 25mg/ml, and gavaging content is 0.4ml/.
The AIb determination of plasma concentration: mice begins fasting the noon before that day of taking medicine, but can't help drinking-water, gavages (ig) AIb Emulsion 1 time inferior morning, and different time cuts open extremely after administration, with plucking the eyeball method, gathers the blood of each Mus, anticoagulant heparin, centrifugal back separated plasma is put in-18 ℃ standby.
Produce the AIb suspension of 1% tragakanta: (following employed this suspension compound method is identical)
Get tragakanta 1 gram,, pour this pastel into add again after the stirring in the 100ml water albendazole and stir the AIb suspension that promptly is mixed with 1% tragakanta with AIb Emulsion same amount with a little 95% ethanol furnishing pastel.
Matched group is with the AIb suspension ig mice of 1% tragakanta preparation, and gets blood compare in the above-mentioned time.
Get and examined blood plasma, press preamble (Wang Mingjie, etc. measure albendazole and major metabolite thereof in the blood plasma, endemic diseases circular 1991 with educating the effect liquid phase chromatogram method; 6 (3): high effective liquid chromatography for measuring AIb 7-11), albendazole-sulfoxide (AIbSO) and Albendazole sulfone (AIbSO
2).Because behind the ig AIb, the rapid metabolism of absorbed AIb is effective metabolite AIbSO, inferior is AIbSO
2, AIb does not then have or trace is only arranged, so in this test, AIbSO system makes the concentration of effective metabolite of the anti-Echinococcus hydatid cyst of AIb, and AIb+AIbSO+AIbSO
2always record the integral dose that thing is then represented AIb, and take statistics according to this and analyze.
The result: 2 groups of mices ig respectively contain the AIb Emulsion of Oleum Glycines 30% and the AIb suspension 300mg/kg of 1% tragakanta, and after administration 0.5,1,2,4,6,8,10,12,16,20 and 24h respectively cut open extremely 5 Mus, get its AIbSO of determination of plasma and always record thing, as table 1.
Draw from experimental result: 1 ig of mice contains 0.5-10h behind the AIb Emulsion 300mg/kg of Oleum Glycines 30%, the AIbSO of its blood plasma and the cumulative amount that always records thing respectively are 45.4 μ g/ml and 59.5 μ g/ml, and be high more than 1 times than the 22.1 μ g/ml and the 28.7 μ g/ml of the AIb group of 1% tragakanta.AIb Emulsion can increase absorption, and blood drug level obviously improves.
Soya-bean oil content AIbSO always records (%) (μ g/ml) (μ g/ml) 1 1% tragacanth 6.9 ± 0.6 8.5 ± 0.7 2 11.8 ± 2.4 15.0 ± 3.0 4 9.7 ± 2.7 12.8 ± 3.6 1 56.7 8.3 ± 2.4 10.8 ± 3.3 2 13.9 ± 2.2 20.4 ± 2.5 of thing time (h) after the blood concentration n=5 administration of table 1. mouse gavaging AIb soya-bean oil emulsion 300mg/kg*4 14.0 ± 1.6
*19.3 ± 1.8
*1 1% tragacanth 7.4 ± 2.5 10.8 ± 2.9 2 5.2 ± 0.4 7.2 ± 0.9 4 5.1 ± 0.9 7.3 ± 0.8 1 30.3 5.6 ± 3.2 7.6 ± 4.4 2 5.5 ± 1.1 8.1 ± 1.9 4 13.2 ± 4.2*18.3 ± 6.4 1 1% tragakanta 2.8 ± 0.3 3.7 ± 0.4 2 3.5 ± 0.9 4.5 ± 1.3 4 4.3 ± 0.7 5.5 ± 0.8 1 20 10.6 ± 1.6
*13.6 ± 1.7
*2 8.5 ± 0.7
*10.7 ± 0.9
*4 10.7 ± 1.4 14.3 ± 1.9
* *P＜0.05,
*Compare with corresponding 1% tragakanta group in P＜0.01
The present invention is remarkable to the echinococcosis therapeutic effect, the mice that infects capsule type Echinococcus hydatid cyst and alveolitoid Echinococcus hydatid cyst is better than the suspensoid of same dose 1% tragakanta with AIb Emulsion therapeutic effect.
Albendazole emulsion is as follows to the efficacy result test of mice echinococcosis:
Infection particulate echinococcus reaches individual month mice of 4-6 and treats with Albendazole emulsion 100mg/kg or 150mg/kg, every day 1 time, connect the heavy matched group that obviously is lighter than of the average capsule of every Mus of giving 14 days, heavy then similar with the flat capsule of every Mus that the albendazole 1% tragakanta suspensoid of same dose is treated with matched group.The mice that infects the alveolar sphere larva of a tapeworm or the cercaria of a schistosome gavages with Albendazole emulsion 25mg/ml every day, serve on 28 days, and the average capsule of its every Mus is heavy obviously to be lighter than matched group, does not have significant difference but gavage the heavy and matched group of the average capsule of every Mus of albendazole suspensoid group of same dose every day.
Be subjected to the reagent thing
Title: Albendazole emulsion.
The unit of providing: Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences.
Lot number: E9601.
Content: the albendazole content available from Han River pharmaceutical factory is 99.1%; The albendazole content of Emulsion is 1.25-7.5mg/ml.
Animal
Come former and kind strain: kunming mouse is provided by Shanghai Chinese Academy of Sciences Experimental Animal Center.
Production licence number: moving word 02-32-1 number of doctor.
Body weight: 20-24g.
Sex: female, male dual-purpose.
Grouping and number of animals: random packet, every group is observed Mus is 14-23.
Test methods and procedures
1, experimental animal model:
(1) particulate echinococcus-mouse model.
(2) the alveolar sphere larva of a tapeworm or the cercaria of a schistosome-mouse model.
2, method and step
(1) inoculation: particulate echinococcus protoscolex is taken from Xinjiang Endemic Disease Prevention and Cure Inst. to be provided.Face with preceding removal capsule axil,, be suspended in then in the Heng Shi salt balance solution that contains penicillin and each 500IU/ml of Streptomycin with Heng Shi salt balance solution washing 5-8 time.Every mice is from lumbar injection particulate echinococcus protoscolex 0.5ml (contain procephalon and save 200).
Protect the infection alveolar sphere larva of a tapeworm or the cercaria of a schistosome mouse peritoneal of planting from laboratory and strip born of the same parents' ball larva of a tapeworm or the cercaria of a schistosome lens capsule tissue, after with shears lens capsule tissue being shredded, with above-mentioned Heng Shi salt balance solution washing 5 times, barreling, suspendible add penicillin and each 500IU/ml of streptomycin then earlier.Get mice and inject alveolar sphere larva of a tapeworm or the cercaria of a schistosome lens capsule tissue suspension 0.5ml from the abdominal cavity, contain lens capsule tissue 40-50mg.
(2) administration: mice behind inoculation particulate echinococcus protoscolex 4-6 month, or inoculation alveolar sphere larva of a tapeworm or the cercaria of a schistosome lens capsule tissue weighs after 1 month, dose (mg/kg) according to the weight, intragastrically treatment.
(3) dissect: the mice that infects the particulate echinococcus or the alveolar sphere larva of a tapeworm or the cercaria of a schistosome is finished back 2-4 week and puts to death with disconnected neck method in controlling, and cuts open in the abdominal cavity, carefully peels off and win particulate sour jujube larva of a tapeworm or the cercaria of a schistosome bladder worm or alveolar sphere larva of a tapeworm or the cercaria of a schistosome capsule, and it is heavy to take by weighing the capsule of every mice.
(4) curative effect: the average capsule that calculates medicine group and matched group is heavy, with t test evaluation curative effect, and calculates the heavy suppression ratio of capsule
The dosage design
Experience design dosage according to the experimental therapy accumulation.
1, particulate echinococcus treatment:
50mg/kg/ days * 14 days, 100mg/kg/ days * 14 days
With 150mg/kg/ days * 14 days.
2, alveolar sphere larva of a tapeworm or the cercaria of a schistosome treatment:
5mg/kg/ days * 28 days and 50mg/kg/ days * 28 days.
Medication
Gastric infusion, the administration capacity of each dosage is the 0.4ml/20g body weight.
Experimental control
1, Albendazole suspension contrast: use the albendazole of producing with a collection of Hanzhong pharmaceutical factory, be prepared into suspensoid with 1% tragakanta and make the positive control medicine.
2, blank: use with a collection of mice infected and will not treat, as blank.
Result of the test
1, Albendazole emulsion is to the curative effect of mice particulate echinococcus
Mice is after infecting 4 months, gavage with Albendazole emulsion 50mg/kg or 100mg/kg every day, in the time of continuous 14 days, the average capsule of every Mus is 603 ± 576mg and 271 ± 126mg heavily fully, significant difference (P＜0.05) with 1393 ± 1642mg of matched group, with the albendazole 1% tragakanta suspensoid treatment of same dose, the average capsule of every Mus weighs the no significant difference (P＞0.05 is as table 2) with matched group.In another test, mice is after infecting 6 months, gavage Albendazole emulsion 150mg/kg every day, serve on 14 days, the average capsule of every Mus heavily is 1624 ± 1597mg, be starkly lower than the 3503 ± 2978mg (P＜0.05) of matched group, 2629 ± 2451mg of the albendazole suspendible group of oral same dose then with the no significant difference (P＞0.05) of matched group.
2, Albendazole emulsion is to the curative effect of the mice alveolar sphere larva of a tapeworm or the cercaria of a schistosome
Mice after infecting the alveolar sphere larva of a tapeworm or the cercaria of a schistosome 1 month, gavage with Albendazole emulsion 25mg/kg or 50mg/kg every day, serve on 28 days, and on average the capsule weight average obviously is lighter than matched group, and the heavy suppression ratio of capsule reaches 71.5% and 78%.With the treatment of albendazole 1% tragakanta of same dose, heavy be evident as light (P＜0.05) of the average capsule of 50mg/ml group only than matched group, but with similar (P＞0.5) of Albendazole emulsion group 25mg/kg group.As table 3.
Conclusion (of pressure testing)
Infect the effect of the mice of the particulate echinococcus and the alveolar sphere larva of a tapeworm or the cercaria of a schistosome, be better than 1% tragakanta suspensoid of identical dosage with the Albendazole emulsion treatment.
The mice that table 2. infects the particulate echinococcus infects the heavy suppression ratio of the heavy capsule of the average capsule of post dose Mus number with the effect albendazole that Albendazole emulsion gavages treatment
Time (moon) (mg/kg/d/ * d) (mg, (%) 1% tragakanta 4 50 * 14 17 1067 ± 1029 of X ± SD)
a23.41% tragakanta 100 * 14 18 771 ± 647
a44.7 Emulsion 50 * 14 15 603 ± 576
b56.7 Emulsion 100 * 14 17 271 ± 126
b80.6 contrast-18 1393 ± 16421% tragakanta 6 150 * 14 16 2629 ± 2451
a25.0 Emulsion 150 * 14 14 1624 ± 1579
b53.6 contrast-19 3503 ± 2978X ± SD, a.P＞0.05, compare with matched group b.P＜0.05
The mice of the table 3. infection alveolar sphere larva of a tapeworm or the cercaria of a schistosome gavages the heavy suppression ratio Emulsion 25 of the heavy capsule of the effect albendazole dosage average capsule of Mus number * 28 16 534 ± 532 of treatment with Albendazole emulsion
b71.5 Emulsion 50 * 28 16 413 ± 287
b78.01% tragakanta 25 * 28 17 887 ± 721
a52.71% tragakanta 50 * 28 15 592 ± 470
b68.5 contrast 23 1876 ± 1543X ± SD, a.P＞0.05, compare with matched group b.P＜0.05 c.P＜0.01
Clinical therapeutic efficacy of the present invention is remarkable, and clinical in Albendazole emulsion 10mg/kg every day treatment echinococcosis 48 examples, 18-24 month cure rate of treatment reaches 95.5%, is better than the capsular 30-40% of Albenza or albendazole.
From Albendazole emulsion, the suspensoid maximum tolerance determination can find that once oral AIb Emulsion of mice and AIb suspensoid maximum tolerated dose are 3g/kg, so its Emulsion toxicity does not increase.
Albendazole emulsion, maximum tolerance determination is as follows:
Once used its median lethal dose(LD 50) of mouse assay for the toxicity of understanding albendazole (AIb) Emulsion, suspensoid, and failed to measure, so measure its maximum tolerated dose.
1% tragakanta AIb suspensoid is by Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences's Pharmacology Lab preparation, and the content of AIb is respectively 3g/kg, 4g/kg, and the amount of gavaging is 0.8ml/20g.
AIb Emulsion is provided by Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences medicine research department, and lot number is 0-9801, and the content of AIb is respectively 3g/kg, 4g/kg, and the amount of gavaging is 0.8ml/20g.
Animal origin: Chinese Academy of Sciences zoopery center
Kunming is Mus, body weight 20-22g, and each 10 of every group of ♂, ♀, the quality certification is: the moving pipe of doctor can No. 005; Mice was observed behind single administration 14 days.
Untoward reaction: four groups of mices do not see that obvious adverse reaction is arranged after the administration, and fur is smooth, and are movable normal.Death condition: AIb Emulsion 4g/kg organizes after administration 1 of 12 days ♂ dead mouse, and albendazole suspensoid 4g/kg organizes after administration 1 of 14 days ♀ dead mouse.AIb Emulsion and 1% tragakanta suspensoid 3g/kg group all do not have dead mouse, as table 4.
Conclusion: the maximum tolerated dose of oral albendazole Emulsion of mice and albendazole suspensoid is 3g/kg.
Table 4 mice oral drugs maximum tolerance determination result
| Medicine | Dosage mg/kg/d | Number of animals | The animal sex | Day by day temperature (℃), humidity (%) and death condition | Add up to | ||||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Death toll (only) | Mortality rate % | ||||
| 27-20 | 27-21 | 20-20 | 24-20 | 29-21 | 20-19 | 22-19 | 19-18 | 19-18 | 20-18 | 22-20 | 23-22 | 26-22 | 28-24 | ||||||
| 90 | 80 | 58 | 86 | 65 | 74 | 83 | 89 | 89 | 84 | 89 | 85 | 85 | 82 | ||||||
| AIb Emulsion | 3000 | 10 | ♀ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ||
| 3000 | 10 | ♂ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |||
| The AIb suspensoid | 3000 | 10 | ♀ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | ||
| 3000 | 10 | ♂ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | |||
| AIb Emulsion | 4000 | 10 | ♀ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | 1 | 5 |
| 4000 | 10 | ♂ | / | / | / | / | / | / | / | / | / | / | / | 1 | / | / | |||
| The AIb suspensoid | 4000 | 10 | ♀ | / | / | / | / | / | / | / | / | / | / | / | / | / | / | 1 | 5 |
| 4000 | 10 | ♂ | / | / | / | / | / | / | / | / | / | / | / | / | / | 1 | |||
The present invention is except that having the significant curative effect echinococcosis, and is also all effective in cure as revolving defect, intestinal gland worm, pig capsule disease to other parasitic disease.
Can increase blood drug level so albendazole is made Emulsion, improve curative effect, not increase toxicity, preparation method is simple and easy, and good stability is easy to promote.
Embodiment:
Embodiment 1: albendazole 6.5 grams, Oleum Glycines 24.98 grams, gum arabic powder 2.68 grams, xanthan rubber powder 0.2 gram, sorbic acid 0.1 gram, vanillin 0.04 gram, sweet glucose 0.015 gram, water 65.485 grams.
Compound method: get albendazole 6.5 grams and Oleum Glycines 24.98 grams, gum arabic powder 2.68 grams, xanthan rubber powder 0.2 gram mix homogeneously adds about 60% of Total Water, start emulsifying to colostrum forms, with sorbic acid 0.1 gram, vanillin 0.04 restrains in addition, and sweet glucose 0.015 gram is put in the container, add and join Ruzhong just after surplus water (stay low amounts of water stand-by) stirs, reuse stays the low amounts of water eluant container, is incorporated in Ruzhong just, the start stirring
Embodiment 2: albendazole 2.5 grams, salad oil 24.98 grams, gum arabic powder 2.68 grams, tragakanta 0.88 gram, benzoic acid 0.18 gram, vanillin 0.04 gram, sweet glucose 0.015 gram, ethanol 2.2 grams, water 66.6 grams.
Compound method: get albendazole 2.5 grams and salad oil 24.98 grams and gum arabic powder 2.68 grams, tragakanta 0.88 gram mix homogeneously, add the about 60% of Total Water, start emulsifying to colostrum forms, in addition with sorbic acid 0.18 gram, vanillin 0.04 gram, sweet glucose 0.015 gram and ethanol 2.2 grams are put in the container, add to join Ruzhong just after surplus water (stay low amounts of water stand-by) stirs, and reuse stays the low amounts of water eluant container, be incorporated in Ruzhong just, the start stirring.
Embodiment 3: albendazole 0.63 gram, Semen Maydis oil 23.0 grams, gum arabic powder 2.15 grams, xanthan rubber powder 0.2 gram, sorbic acid 0.1 gram, vanillin 0.04 gram, sweet glucose 0.015 gram, water 73.87 grams.
Compound method: compound method is identical with embodiment 1, just Oleum Glycines is changed to Semen Maydis oil.
Most preferred embodiment: albendazole 1.25 grams, Oleum Glycines 24.98 grams, gum arabic powder 2.68 grams, xanthan rubber powder 0.2 gram, sorbic acid 0.1 gram, vanillin 0.04 gram, sweet glucose 0.015 gram, water 70.74 grams.
Compound method: compound method: identical with embodiment 1.
Instructions of taking: oral 100mg/kg and 12.5mg/kg, obeyed 6-12 hour continuously.
Above embodiment is only for the invention will be further described, and the present invention is not subjected to the limitation of illustrated embodiment.
Claims (4)
1. Albendazole emulsion of using in parasitic disease is characterized in that containing percentage by weight and is:
Albendazole 0.125-10.0
Edible fats 10-57
Emulsifying agent 1-4
Antiseptic 0.1-0.18
Flavoring agent 0.015-0.1
Water adds to 100
2. Albendazole emulsion according to claim 1 is characterized in that the every gram content of described albendazole is 6.25-25mg.
3. Albendazole emulsion according to claim 1 is used to prepare the purposes of the medicine for the treatment of echinococcosis.
4. Albendazole emulsion according to claim 1 is used to prepare the purposes that the medicine of defect, intestinal gland worm and pork measles is revolved in treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99113446 CN1107501C (en) | 1999-01-29 | 1999-01-29 | Albendazole emulsion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99113446 CN1107501C (en) | 1999-01-29 | 1999-01-29 | Albendazole emulsion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1262099A CN1262099A (en) | 2000-08-09 |
| CN1107501C true CN1107501C (en) | 2003-05-07 |
Family
ID=5276636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99113446 Expired - Lifetime CN1107501C (en) | 1999-01-29 | 1999-01-29 | Albendazole emulsion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1107501C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274174B (en) * | 2010-03-18 | 2013-02-13 | 中国疾病预防控制中心寄生虫病预防控制所 | Oil suspension agent of benzimidazole medicine |
| CN104274403B (en) * | 2014-10-14 | 2017-05-31 | 成都乾坤动物药业有限公司 | A kind of Fenbendazole emulsion |
| CN105534900A (en) * | 2016-01-21 | 2016-05-04 | 陈小媚 | Albendazole emulsion and preparation method thereof |
| CN105640891B (en) * | 2016-01-27 | 2018-09-28 | 成都乾坤动物药业有限公司 | A kind of albendazole dried emulsifier and its preparation method and application |
| CN113398134A (en) * | 2021-07-08 | 2021-09-17 | 新疆医科大学第一附属医院 | Application of insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of medicine for treating cystic echinococcosis |
-
1999
- 1999-01-29 CN CN 99113446 patent/CN1107501C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1262099A (en) | 2000-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102274174B (en) | Oil suspension agent of benzimidazole medicine | |
| CN1709248A (en) | Lansoprazole lyophilized powder injection and its preparing method | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1107501C (en) | Albendazole emulsion | |
| CN1843333A (en) | Sodium hyaluronate carulon fat emulsion formulation and its uses | |
| CN1810794A (en) | Prepn process and medicine composition of dewatered andrographolide | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1742871A (en) | Gamboge bone-tonifying preparation and new preparation method thereof | |
| CN1176697C (en) | Antisenility medicine composition and its prepn | |
| CN1602855A (en) | Application of forsythin in the process for preparing adiposis treating oral medicine and healthy food | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1415303A (en) | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia | |
| CN1939328A (en) | Puerarin injection | |
| CN1718578A (en) | Lerivisiticum extract, its preparation method and medicine containing said extract | |
| CN1299684C (en) | Antibacterial for aquatic animal, preparing method and method of feeding medicine | |
| CN1504191A (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN1895298A (en) | Medicinal preparation for treating and preventing coronary heart disease and thromboembolia disease and its preparation | |
| CN1879777A (en) | Blood circulation-invigorating tendon-strengthening preparation and method for preparing same | |
| CN1857255A (en) | Bilobalide B emulsion for injection | |
| CN1257713C (en) | Flunarizine hydrochloride injection and its preparing method | |
| CN1943720A (en) | A Chinese traditional medical preparation for treating lumbocrural pains, dizziness and tinnitus etc. | |
| CN1768775A (en) | Prescription containing sweet clover component and its formulation | |
| CN1824111A (en) | Cold dissipating network vessel quickening medicinal preparation and its new preparation method | |
| CN1582946A (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHAANXI HANJIANG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: INST. OF PARASITIC DISEASE, CHINESE ACADEMY OF PREVENTIVE MEDICAL SCIENCES Effective date: 20120217 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200025 LUWAN, SHANGHAI TO: 723000 HANZHONG, SHAANXI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120217 Address after: 723000 Hantai District, Shaanxi, Hanzhoung Patentee after: SHAANXI HANJIANG PHARMACEUTICAL GROUP CO., LTD. Address before: 200025 No. two, 207, Ruijin, Shanghai Patentee before: Inst. of Parasitic Disease, Chinese Academy of Preventive Medical Sciences |
|
| CX01 | Expiry of patent term |
Granted publication date: 20030507 |
|
| CX01 | Expiry of patent term |